Saturday 17 October 2026
Export CANF’s income statement to Excel — free account
Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
1.76
0.09
−4.86%
Follow CANF
| Older periods | Sep '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(140.94%) | 0.00% | 0.00% | 0.00% | |
| (81.58%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(129.29%) | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (18.64) | (19.92) | (19.15) | |
Capital Expenditures |
— | (0.02) | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
0.00% | (258.71%) | (187.25%) | (160.99%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
915.12% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
390.01% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.72 | 7.60 | 6.60 | |
Capex/Depreciation |
— | (0.83) | (0.32) | (0.24) | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates